RxDoctor Payments Data

Nicole Ng

Pulmonary Disease · New York, NYNPI 1073892907

Payments from drug & device makers

$68,474in general payments, 2019–2025

Across 57 payments — averaging $1201.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$42K
  • Sanofi$17K
  • Boehringer Ingelheim International GmbH$8K
  • Mallinckrodt Hospital Products Inc.$438
  • Intuitive Surgical$242
  • GSK$125
  • plus $117 from 1 others

What the payments were for

  • Consulting fees$15,60683%
  • Travel & lodging$1,1536%
  • Food & beverage$2,00411%
  • Gifts$140%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,474 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$75,971
Medicare patients
175
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate108$980,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$81,755
Breo ElliptaFluticasone/Vilanterol40$18,684
Incruse ElliptaUmeclidinium Bromide40$14,624
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,816
Pirfenidone19$12,374
Mycophenolate Mofetil80$12,307
SymbicortBudesonide/Formoterol Fumarate21$8,983
MresviaRsv Vaccine, Pref, Mrna/Pf30$8,817
ArexvyRsvpref3 Antigen/As01e/Pf28$8,065
Albuterol Sulfate HfaAlbuterol Sulfate145$4,616
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,452
Ventolin HfaAlbuterol Sulfate15$815
Prednisone123$566
Fluticasone Propionate35$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$42,273$980,695108 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arexvy$125$135,944221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →